Private, clinical-stage IO company developing unique approach to antigen-specific T cell therapy. Synthetic nanoparticles decorated w a combo of multiple tumor relevant antigens and co-stimulatory signals engaging directly w targeted T cells to orchestrate specific immune responses to cancer. Product applications as both SQ injectable and adoptively transferred cellular therapy. Two Ph 1's ongoing.
US - South Atlantic
Phase l or ll, Pre-Clinical Stage
9119 Gaither Road
Gaithersburg, MD 20877
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.